Special meeting of Foresight Acquisition Corp. stockholders to approve the proposed business combination to be held on November 18, 2021 at 9:00 a.m. Central Time.

NEW YORK, Oct. 29, 2021 (GLOBE NEWSWIRE) -- Foresight Acquisition Corp. (NASDAQ:FORE) (“Foresight”) and P3 Health Partners (“P3”), a patient centered and physician led population health management company, announced that on October 28, 2021, Foresight filed a definitive proxy statement (the "Proxy Statement") relating to the proposed business combination (the “Business Combination”) with P3. Foresight also announced that a special meeting of its stockholders will be held at 9:00 a.m. Central Time on November 18, 2021, in connection with the Business Combination (the “Special Meeting”). The Proxy Statement is being mailed to Foresight’s stockholders of record as of the close of business on October 8, 2021.

If the proposals at the Special Meeting are approved, the parties anticipate that the Business Combination will close as promptly as practicable after the meeting, subject to the satisfaction or waiver (as applicable) of all other closing conditions.

Upon closing of the Business Combination, the combined company will be named P3 Health Partners Inc. and will be listed on the NASDAQ under the new ticker symbol "PIII."

“We are excited to have reached this important milestone,” said Sherif Abdou, CEO of P3. “With our deep value-based care expertise and proven track record for addressing some of the largest challenges in healthcare today, we look forward to successfully completing the proposed Business Combination and providing more high-quality care in order to improve patient outcomes and reduce medical costs.”

Greg Wasson, Chairman of Foresight, commented: “The Foresight team is excited to be moving forward with this exceptional opportunity and work closely with the P3 leadership team to combine our healthcare and public company experience with P3’s deep expertise in value-based care.”